You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTreprostinil
Accession NumberDB00374  (APRD01272)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionTreprostinil is a synthetic analogue of prostacyclin, used to treat pulmonary hypertension. Treprostinil is marketed as Remodulin®. [Wikipedia]
Structure
Thumb
Synonyms
(1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-hexahydro-2-hydroxy- 1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl] oxy]acetic acid
[[(1R,2R,3aS,9aS)-2-Hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphtalen-5-yl]oxy]acetic acid
Treprostinil
Treprostinilo
Treprostinilum
Uniprost
External Identifiers
  • 15AU81
  • BW 15AU
  • LRX 15
  • U 62840
  • UT 15
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
OrenitramTablet, extended release1 mg/1OralUnited Therapeutics Corp.2013-12-20Not applicableUs
OrenitramTablet, extended release2.5 mg/1OralUnited Therapeutics Corp.2013-12-20Not applicableUs
OrenitramTablet, extended release.125 mg/1OralUnited Therapeutics Corp.2013-12-20Not applicableUs
OrenitramTablet, extended release5 mg/1OralUnited Therapeutics Corp.2013-12-20Not applicableUs
OrenitramTablet, extended release.25 mg/1OralUnited Therapeutics Corp.2013-12-20Not applicableUs
RemodulinSolution10 mgIntravenous; SubcutaneousUnited Therapeutics Corporation2004-04-30Not applicableCanada
RemodulinInjection, solution20 mg/20mLIntravenous; SubcutaneousUnited Therapeutics Corporation2002-05-22Not applicableUs
RemodulinSolution1 mgIntravenous; SubcutaneousUnited Therapeutics Corporation2004-04-30Not applicableCanada
RemodulinInjection, solution50 mg/20mLIntravenous; SubcutaneousUnited Therapeutics Corporation2002-05-22Not applicableUs
RemodulinSolution2.5 mgIntravenous; SubcutaneousUnited Therapeutics Corporation2004-04-30Not applicableCanada
RemodulinInjection, solution100 mg/20mLIntravenous; SubcutaneousUnited Therapeutics Corporation2002-05-22Not applicableUs
RemodulinSolution5 mgIntravenous; SubcutaneousUnited Therapeutics Corporation2004-04-30Not applicableCanada
RemodulinInjection, solution200 mg/20mLIntravenous; SubcutaneousUnited Therapeutics Corporation2002-05-22Not applicableUs
TyvasoInhalant1.74 mg/2.9mLOralUnited Therapeutics Corp.2009-08-14Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Treprostinil diolamine
ThumbNot applicableDBSALT001333
Categories
UNIIRUM6K67ESG
CAS number81846-19-7
WeightAverage: 390.5131
Monoisotopic: 390.240624198
Chemical FormulaC23H34O5
InChI KeyPAJMKGZZBBTTOY-ZFORQUDYSA-N
InChI
InChI=1S/C23H34O5/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25/h5-6,8,16-19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27)/t16-,17-,18+,19-,21+/m0/s1
IUPAC Name
2-{[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-1H,2H,3H,3aH,4H,9H,9aH-cyclopenta[b]naphthalen-5-yl]oxy}acetic acid
SMILES
[H][C@]12C[C@@H](O)[[email protected]](CC[C@@H](O)CCCCC)[C@@]1([H])CC1=C(C2)C(OCC(O)=O)=CC=C1
Pharmacology
IndicationFor use as a continuous subcutaneous infusion or intravenous infusion (for those not able to tolerate a subcutaneous infusion) for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise.
Structured Indications
PharmacodynamicsPulmonary arterial hypertension (PAH) is a disease in which blood pressure is abnormally high in the arteries between the heart and lungs. PAH is characterized by symptoms of shortness of breath during physical exertion. The condition can ultimately lead to heart failure. Treprostinil is a potent oral antiplatelet agent. The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation. In animals, the vasodilatory effects reduce right and left ventricular afterload and increase cardiac output and stroke volume. Other studies have shown that treprostinil causes a dose-related negative inotropic and lusitropic effect. No major effects on cardiac conduction have been observed.
Mechanism of actionThe major pharmacological actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation. In addition to treprostinil's direct vasodilatory effects, it also inhibits inflammatory cytokine. As a synthetic analogue of prostacyclin, it binds to the prostacyclin receptor, which subsequently induces the aforementioned downstream effects.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostacyclin receptorProteinyes
agonist
HumanP43119 details
Peroxisome proliferator-activated receptor deltaProteinyes
agonist
HumanQ03181 details
P2Y purinoceptor 12Proteinyes
agonist
HumanQ9H244 details
Related Articles
AbsorptionRelatively rapid and complete after subcutaneous infusion, with an absolute bioavailability approximately 100%. In patients with mild (n=4) or moderate (n=5) hepatic insufficiency and portopulmonary hypertension following a subcutaneous dose of 10 ng per kg of body weight per min for 150 mins the AUC 0-∞ was increased 3-fold and 5-fold respectively.
Volume of distribution
  • 14 L/70 kg
Protein bindingHuman plasma protein binding is approximately 91% in in vitro concentrations ranging from 330 to 10,000 µ/L.
Metabolism

Substantially metabolized by the liver, but the precise enzymes responsible are unknown. Five metabolites have been described (HU1 through HU5) however, the biological activity and metabolic fate of these are unknown. The chemical structure of HU1 is unknown. The metabolite HU5 is the glucuronide conjugate of treprostinil. The other metabolites are formed by oxidation of the 3-hydroxyoctyl side chain (HU2) and subsequent additional oxidation (HU3) or dehydration (HU4). Study results of in vitro human hepatic cytochrome P450 demonstrates that treprostinil does not inhibit CYP-1A2, 2C9, 2C19, 2D6, 2E1, or 3A. Whether treprostinil induces these enzymes has not been studied.

Route of eliminationNot Available
Half lifeTerminal elimination half-life is approximately 2 to 4 hours. Plasma half-life is 34 and 85 minutes for intravenous and subcutaneous infusion of the drug, respectively.
ClearanceNot Available
ToxicitySymptoms of overdose are extensions of its dose-limiting pharmacologic effects and include flushing, headache, hypotension, nausea, vomiting, and diarrhea. Most events were self-limiting and resolved with reduction or withholding of treprostinil.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Treprostinil.Experimental
AbciximabTreprostinil may increase the antiplatelet activities of Abciximab.Approved
AbirateroneThe metabolism of Treprostinil can be decreased when combined with Abiraterone.Approved
AcebutololTreprostinil may increase the hypotensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Treprostinil is combined with Aceclofenac.Approved
AcenocoumarolTreprostinil may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Treprostinil is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Treprostinil is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Treprostinil is combined with Adapalene.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Treprostinil.Approved, Investigational
AliskirenTreprostinil may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololTreprostinil may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AlprostadilTreprostinil may increase the antiplatelet activities of Alprostadil.Approved, Investigational
AlteplaseThe risk or severity of adverse effects can be increased when Alteplase is combined with Treprostinil.Approved
ALX-0081The risk or severity of adverse effects can be increased when ALX-0081 is combined with Treprostinil.Investigational
AmbrisentanTreprostinil may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineTreprostinil may increase the hypotensive activities of Amifostine.Approved, Investigational
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Treprostinil is combined with Aminosalicylic Acid.Approved
AmiodaroneTreprostinil may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmlodipineTreprostinil may increase the hypotensive activities of Amlodipine.Approved
AnagrelideTreprostinil may increase the QTc-prolonging activities of Anagrelide.Approved
AncrodTreprostinil may increase the anticoagulant activities of Ancrod.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Anisodamine.Investigational
AnistreplaseThe risk or severity of adverse effects can be increased when Anistreplase is combined with Treprostinil.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Antipyrine.Approved
Antithrombin III humanTreprostinil may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanTreprostinil may increase the anticoagulant activities of Apixaban.Approved
ApremilastThe risk or severity of adverse effects can be increased when Treprostinil is combined with Apremilast.Approved, Investigational
AprepitantThe metabolism of Treprostinil can be increased when combined with Aprepitant.Approved, Investigational
AprotininThe therapeutic efficacy of Treprostinil can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArdeparinTreprostinil may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanTreprostinil may increase the antiplatelet activities of Argatroban.Approved, Investigational
Arsenic trioxideTreprostinil may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherTreprostinil may increase the QTc-prolonging activities of Artemether.Approved
AsenapineTreprostinil may increase the QTc-prolonging activities of Asenapine.Approved
AstaxanthinThe risk or severity of adverse effects can be increased when Astaxanthin is combined with Treprostinil.Investigational
AtenololAtenolol may increase the hypotensive activities of Treprostinil.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Treprostinil is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Azelastine.Approved
AzithromycinTreprostinil may increase the QTc-prolonging activities of Azithromycin.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Treprostinil is combined with Balsalazide.Approved, Investigational
BatroxobinThe risk or severity of adverse effects can be increased when Batroxobin is combined with Treprostinil.Experimental
BecaplerminTreprostinil may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BedaquilineTreprostinil may increase the QTc-prolonging activities of Bedaquiline.Approved
BemiparinThe risk or severity of adverse effects can be increased when Bemiparin is combined with Treprostinil.Approved
BenazeprilTreprostinil may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideTreprostinil may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Treprostinil.Withdrawn
BenoxaprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Benoxaprofen.Withdrawn
BepridilTreprostinil may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BeraprostTreprostinil may increase the antiplatelet activities of Beraprost.Investigational
BetaxololBetaxolol may increase the hypotensive activities of Treprostinil.Approved
BethanidineBethanidine may increase the hypotensive activities of Treprostinil.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Treprostinil is combined with Betulinic Acid.Investigational
BimatoprostTreprostinil may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololTreprostinil may increase the hypotensive activities of Bisoprolol.Approved
BivalirudinTreprostinil may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BosentanTreprostinil may increase the hypotensive activities of Bosentan.Approved, Investigational
BretyliumTreprostinil may increase the hypotensive activities of Bretylium.Approved
BrimonidineTreprostinil may increase the hypotensive activities of Brimonidine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Treprostinil.Approved
BromfenacThe risk or severity of adverse effects can be increased when Treprostinil is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Bucillamine.Investigational
BupranololTreprostinil may increase the hypotensive activities of Bupranolol.Approved
ButylphthalideTreprostinil may increase the antiplatelet activities of Butylphthalide.Investigational
CandesartanTreprostinil may increase the hypotensive activities of Candesartan.Approved
CandoxatrilTreprostinil may increase the hypotensive activities of Candoxatril.Experimental
CangrelorTreprostinil may increase the antiplatelet activities of Cangrelor.Approved
CapecitabineThe metabolism of Treprostinil can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilTreprostinil may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe serum concentration of Treprostinil can be decreased when it is combined with Carbamazepine.Approved, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Treprostinil.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololTreprostinil may increase the hypotensive activities of Carteolol.Approved
CarvedilolTreprostinil may increase the hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Treprostinil is combined with Celecoxib.Approved, Investigational
CeliprololTreprostinil may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Treprostinil can be increased when it is combined with Ceritinib.Approved
CertoparinTreprostinil may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideTreprostinil may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorpromazineTreprostinil may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Treprostinil.Approved
CholecalciferolThe metabolism of Treprostinil can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilTreprostinil may increase the hypotensive activities of Cilazapril.Approved
CilostazolTreprostinil may increase the antiplatelet activities of Cilostazol.Approved
CiprofloxacinTreprostinil may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideTreprostinil may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramTreprostinil may increase the QTc-prolonging activities of Citalopram.Approved
Citric AcidTreprostinil may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinTreprostinil may increase the QTc-prolonging activities of Clarithromycin.Approved
ClonidineTreprostinil may increase the hypotensive activities of Clonidine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Treprostinil is combined with Clonixin.Approved
ClopidogrelThe serum concentration of Treprostinil can be increased when it is combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe metabolism of Treprostinil can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineTreprostinil may increase the QTc-prolonging activities of Clozapine.Approved
CrizotinibTreprostinil may increase the QTc-prolonging activities of Crizotinib.Approved
CryptenamineTreprostinil may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Treprostinil is combined with Curcumin.Investigational
CyclosporineThe metabolism of Treprostinil can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideTreprostinil may increase the hypotensive activities of Cyclothiazide.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Treprostinil is combined with D-Limonene.Investigational
Dabigatran etexilateTreprostinil may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Treprostinil can be decreased when it is combined with Dabrafenib.Approved
DalteparinTreprostinil may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidTreprostinil may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DebrisoquinTreprostinil may increase the hypotensive activities of Debrisoquin.Approved
DefibrotideTreprostinil may increase the antiplatelet activities of Defibrotide.Approved, Investigational
DelavirdineThe metabolism of Treprostinil can be decreased when combined with Delavirdine.Approved
dersalazineThe risk or severity of adverse effects can be increased when Treprostinil is combined with dersalazine.Investigational
DeserpidineTreprostinil may increase the hypotensive activities of Deserpidine.Approved
DesirudinTreprostinil may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseThe risk or severity of adverse effects can be increased when Desmoteplase is combined with Treprostinil.Investigational
DextranTreprostinil may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Treprostinil may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Treprostinil may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Treprostinil may increase the anticoagulant activities of Dextran 75.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Treprostinil.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Treprostinil is combined with Diclofenac.Approved, Vet Approved
DicoumarolTreprostinil may increase the anticoagulant activities of Dicoumarol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Treprostinil is combined with Diflunisal.Approved
DihydralazineTreprostinil may increase the hypotensive activities of Dihydralazine.Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Treprostinil.Approved
DipyridamoleTreprostinil may increase the antiplatelet activities of Dipyridamole.Approved
DisopyramideTreprostinil may increase the QTc-prolonging activities of Disopyramide.Approved
DitazoleThe risk or severity of adverse effects can be increased when Ditazole is combined with Treprostinil.Approved, Withdrawn
DofetilideTreprostinil may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronTreprostinil may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneTreprostinil may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DorzolamideTreprostinil may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinTreprostinil may increase the hypotensive activities of Doxazosin.Approved
DronedaroneTreprostinil may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolTreprostinil may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
Drotrecogin alfaThe risk or severity of adverse effects can be increased when Drotrecogin alfa is combined with Treprostinil.Approved, Investigational, Withdrawn
DroxicamThe risk or severity of adverse effects can be increased when Treprostinil is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Treprostinil is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Treprostinil is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Ebselen.Investigational
Edetic AcidTreprostinil may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanTreprostinil may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Treprostinil can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineTreprostinil may increase the hypotensive activities of Efonidipine.Approved
EliglustatTreprostinil may increase the QTc-prolonging activities of Eliglustat.Approved
EnalaprilTreprostinil may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatTreprostinil may increase the hypotensive activities of Enalaprilat.Approved
EnoxaparinTreprostinil may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineTreprostinil may increase the antiplatelet activities of Epinastine.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Treprostinil is combined with Epirizole.Approved
eplivanserineTreprostinil may increase the antiplatelet activities of eplivanserine.Investigational
EpoprostenolTreprostinil may increase the antiplatelet activities of Epoprostenol.Approved
EprosartanTreprostinil may increase the hypotensive activities of Eprosartan.Approved
EptifibatideTreprostinil may increase the antiplatelet activities of Eptifibatide.Approved, Investigational
ErythromycinTreprostinil may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramTreprostinil may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Treprostinil is combined with Etanercept.Approved, Investigational
EthanolEthanol can cause an increase in the absorption of Treprostinil resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
Ethyl biscoumacetateTreprostinil may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacThe risk or severity of adverse effects can be increased when Treprostinil is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Treprostinil is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Treprostinil is combined with Etoricoxib.Approved, Investigational
EtravirineThe metabolism of Treprostinil can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Treprostinil is combined with exisulind.Investigational
FelodipineTreprostinil may increase the hypotensive activities of Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Fenbufen.Approved
FenoldopamTreprostinil may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Fenoprofen.Approved
FibrinolysinThe risk or severity of adverse effects can be increased when Fibrinolysin is combined with Treprostinil.Approved
FlecainideTreprostinil may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FloctafenineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Floctafenine.Approved, Withdrawn
FloxuridineThe metabolism of Treprostinil can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Treprostinil can be decreased when combined with Fluconazole.Approved
FluindioneTreprostinil may increase the anticoagulant activities of Fluindione.Investigational
FlunixinThe risk or severity of adverse effects can be increased when Treprostinil is combined with Flunixin.Vet Approved
FluorouracilThe metabolism of Treprostinil can be decreased when combined with Fluorouracil.Approved
FluoxetineTreprostinil may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolTreprostinil may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FlurbiprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Flurbiprofen.Approved, Investigational
FluvastatinThe metabolism of Treprostinil can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Treprostinil can be decreased when combined with Fluvoxamine.Approved, Investigational
FondaparinuxTreprostinil may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumTreprostinil may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FosinoprilTreprostinil may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinThe serum concentration of Treprostinil can be decreased when it is combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Treprostinil.Approved, Vet Approved
GabexateTreprostinil may increase the anticoagulant activities of Gabexate.Investigational
Gadobenic acidTreprostinil may increase the QTc-prolonging activities of Gadobenic acid.Approved
GemfibrozilThe serum concentration of Treprostinil can be increased when it is combined with Gemfibrozil.Approved
GemifloxacinTreprostinil may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GoserelinTreprostinil may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronTreprostinil may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanabenzTreprostinil may increase the hypotensive activities of Guanabenz.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Treprostinil.Approved
GuanethidineTreprostinil may increase the hypotensive activities of Guanethidine.Approved
GuanfacineTreprostinil may increase the hypotensive activities of Guanfacine.Approved, Investigational
HaloperidolTreprostinil may increase the QTc-prolonging activities of Haloperidol.Approved
HeparinTreprostinil may increase the anticoagulant activities of Heparin.Approved, Investigational
HexamethoniumTreprostinil may increase the hypotensive activities of Hexamethonium.Experimental
HigenamineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Higenamine.Investigational
HirulogTreprostinil may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when Treprostinil is combined with HMPL-004.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Treprostinil.Approved
HydralazineTreprostinil may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideTreprostinil may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideTreprostinil may increase the hypotensive activities of Hydroflumethiazide.Approved
IbudilastTreprostinil may increase the antiplatelet activities of Ibudilast.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Treprostinil is combined with Ibuproxam.Withdrawn
IbutilideTreprostinil may increase the QTc-prolonging activities of Ibutilide.Approved
IcatibantThe risk or severity of adverse effects can be increased when Treprostinil is combined with Icatibant.Approved
Icosapent ethylTreprostinil may increase the antiplatelet activities of Icosapent ethyl.Approved, Nutraceutical
idraparinuxTreprostinil may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilTreprostinil may increase the antiplatelet activities of Ifenprodil.Approved, Withdrawn
IloperidoneTreprostinil may increase the QTc-prolonging activities of Iloperidone.Approved
IloprostTreprostinil may increase the antiplatelet activities of Iloprost.Approved, Investigational
ImidaprilTreprostinil may increase the hypotensive activities of Imidapril.Investigational
IndapamideTreprostinil may increase the hypotensive activities of Indapamide.Approved
IndenololTreprostinil may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Treprostinil can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Treprostinil.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Treprostinil is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Indoprofen.Withdrawn
IndoraminTreprostinil may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Treprostinil.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Treprostinil.Withdrawn
IrbesartanThe metabolism of Treprostinil can be decreased when combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Treprostinil.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Treprostinil is combined with Isoxicam.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Treprostinil.Approved
Kct 0809The risk or severity of adverse effects can be increased when Kct 0809 is combined with Treprostinil.Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Treprostinil is combined with Kebuzone.Experimental
KetanserinTreprostinil may increase the antiplatelet activities of Ketanserin.Investigational
KetoconazoleThe metabolism of Treprostinil can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Treprostinil is combined with Ketorolac.Approved
LabetalolTreprostinil may increase the hypotensive activities of Labetalol.Approved
LacidipineTreprostinil may increase the hypotensive activities of Lacidipine.Approved
LatanoprostTreprostinil may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Treprostinil is combined with Leflunomide.Approved, Investigational
LenvatinibTreprostinil may increase the QTc-prolonging activities of Lenvatinib.Approved
LepirudinTreprostinil may increase the anticoagulant activities of Lepirudin.Approved
LercanidipineTreprostinil may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LeuprolideTreprostinil may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevofloxacinTreprostinil may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Treprostinil.Approved
LisinoprilTreprostinil may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Lisofylline.Investigational
LofexidineTreprostinil may increase the hypotensive activities of Lofexidine.Approved, Investigational
LopinavirThe serum concentration of Treprostinil can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Treprostinil is combined with Lornoxicam.Approved
LosartanThe metabolism of Treprostinil can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Treprostinil can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Loxoprofen.Approved
LumacaftorThe serum concentration of Treprostinil can be decreased when it is combined with Lumacaftor.Approved
LumefantrineTreprostinil may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Treprostinil is combined with Lumiracoxib.Approved, Investigational
MacitentanTreprostinil may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Treprostinil is combined with Magnesium salicylate.Approved
ManidipineTreprostinil may increase the hypotensive activities of Manidipine.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Treprostinil is combined with Masoprocol.Approved
MebanazineMebanazine may increase the hypotensive activities of Treprostinil.Withdrawn
MecamylamineTreprostinil may increase the hypotensive activities of Mecamylamine.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Treprostinil is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Treprostinil is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Treprostinil is combined with Meloxicam.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Treprostinil is combined with Metamizole.Withdrawn
MethadoneTreprostinil may increase the QTc-prolonging activities of Methadone.Approved
MethyldopaTreprostinil may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Treprostinil.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Treprostinil.Approved, Investigational
MetipranololTreprostinil may increase the hypotensive activities of Metipranolol.Approved
MetolazoneTreprostinil may increase the hypotensive activities of Metolazone.Approved
MetoprololMetoprolol may increase the hypotensive activities of Treprostinil.Approved, Investigational
MetyrosineTreprostinil may increase the hypotensive activities of Metyrosine.Approved
MibefradilTreprostinil may increase the hypotensive activities of Mibefradil.Withdrawn
MifepristoneThe serum concentration of Treprostinil can be increased when it is combined with Mifepristone.Approved, Investigational
MilrinoneTreprostinil may increase the antiplatelet activities of Milrinone.Approved
MinaprineMinaprine may increase the hypotensive activities of Treprostinil.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Treprostinil.Approved
MizoribineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Treprostinil.Approved
MoexiprilTreprostinil may increase the hypotensive activities of Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Treprostinil.Approved
MoxifloxacinTreprostinil may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineTreprostinil may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Treprostinil is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Treprostinil is combined with Nabumetone.Approved
NadololTreprostinil may increase the hypotensive activities of Nadolol.Approved
NadroparinTreprostinil may increase the anticoagulant activities of Nadroparin.Approved
NafamostatThe risk or severity of adverse effects can be increased when Treprostinil is combined with Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Naftifine.Approved
NaftopidilTreprostinil may increase the antiplatelet activities of Naftopidil.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Naproxen.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when Treprostinil is combined with NCX 4016.Investigational
NebivololTreprostinil may increase the hypotensive activities of Nebivolol.Approved, Investigational
NepafenacThe risk or severity of adverse effects can be increased when Treprostinil is combined with Nepafenac.Approved
NialamideNialamide may increase the hypotensive activities of Treprostinil.Withdrawn
NicardipineThe metabolism of Treprostinil can be decreased when combined with Nicardipine.Approved
NicorandilTreprostinil may increase the hypotensive activities of Nicorandil.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Treprostinil is combined with Niflumic Acid.Approved
NiguldipineTreprostinil may increase the hypotensive activities of Niguldipine.Experimental
NilotinibTreprostinil may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilvadipineTreprostinil may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Treprostinil is combined with Nimesulide.Approved, Withdrawn
NimodipineTreprostinil may increase the hypotensive activities of Nimodipine.Approved
NisoldipineTreprostinil may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineTreprostinil may increase the hypotensive activities of Nitrendipine.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Treprostinil is combined with Nitroaspirin.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Treprostinil.Approved
ObinutuzumabTreprostinil may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Treprostinil.Withdrawn
OfloxacinTreprostinil may increase the QTc-prolonging activities of Ofloxacin.Approved
OlmesartanOlmesartan may increase the hypotensive activities of Treprostinil.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Olsalazine.Approved
OmapatrilatTreprostinil may increase the hypotensive activities of Omapatrilat.Investigational
OmeprazoleThe metabolism of Treprostinil can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronTreprostinil may increase the QTc-prolonging activities of Ondansetron.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Treprostinil is combined with Orgotein.Vet Approved
OtamixabanTreprostinil may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Treprostinil is combined with Oxaprozin.Approved
OxprenololTreprostinil may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Treprostinil is combined with Oxyphenbutazone.Withdrawn
PaliperidoneTreprostinil may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatTreprostinil may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
ParecoxibThe risk or severity of adverse effects can be increased when Treprostinil is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Treprostinil.Approved
ParnaparinThe risk or severity of adverse effects can be increased when Parnaparin is combined with Treprostinil.Approved
PazopanibTreprostinil may increase the QTc-prolonging activities of Pazopanib.Approved
PenbutololTreprostinil may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineTreprostinil may increase the QTc-prolonging activities of Pentamidine.Approved
PentoliniumTreprostinil may increase the hypotensive activities of Pentolinium.Approved
Pentosan PolysulfateTreprostinil may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Treprostinil.Approved, Investigational
PerflutrenTreprostinil may increase the QTc-prolonging activities of Perflutren.Approved
PerindoprilTreprostinil may increase the hypotensive activities of Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Treprostinil.Approved
PhenindioneTreprostinil may increase the anticoagulant activities of Phenindione.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Treprostinil.Withdrawn
PhenobarbitalThe serum concentration of Treprostinil can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineTreprostinil may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Treprostinil.Withdrawn
PhenprocoumonTreprostinil may increase the anticoagulant activities of Phenprocoumon.Approved
PhentolamineTreprostinil may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Treprostinil is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe serum concentration of Treprostinil can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Treprostinil is combined with Pimecrolimus.Approved, Investigational
PimozideTreprostinil may increase the QTc-prolonging activities of Pimozide.Approved
PinacidilTreprostinil may increase the hypotensive activities of Pinacidil.Withdrawn
PindololTreprostinil may increase the hypotensive activities of Pindolol.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Treprostinil is combined with Pirfenidone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Treprostinil.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Treprostinil is combined with Piroxicam.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Treprostinil.Withdrawn
PlasminThe risk or severity of adverse effects can be increased when Plasmin is combined with Treprostinil.Investigational
PolythiazideTreprostinil may increase the hypotensive activities of Polythiazide.Approved
PrasugrelTreprostinil may increase the antiplatelet activities of Prasugrel.Approved
PrazosinTreprostinil may increase the hypotensive activities of Prazosin.Approved
PrimaquineTreprostinil may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe serum concentration of Treprostinil can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcainamideTreprostinil may increase the QTc-prolonging activities of Procainamide.Approved
PromazineTreprostinil may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Treprostinil is combined with Propacetamol.Approved
PropafenoneTreprostinil may increase the QTc-prolonging activities of Propafenone.Approved
PropranololTreprostinil may increase the hypotensive activities of Propranolol.Approved, Investigational
Protein CTreprostinil may increase the anticoagulant activities of Protein C.Approved
Protein S humanTreprostinil may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeTreprostinil may increase the anticoagulant activities of Protocatechualdehyde.Approved
PTC299The risk or severity of adverse effects can be increased when Treprostinil is combined with PTC299.Investigational
PyrimethamineThe metabolism of Treprostinil can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuetiapineTreprostinil may increase the QTc-prolonging activities of Quetiapine.Approved
QuinaprilTreprostinil may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinidineTreprostinil may increase the QTc-prolonging activities of Quinidine.Approved
QuinineTreprostinil may increase the QTc-prolonging activities of Quinine.Approved
RamatrobanTreprostinil may increase the antiplatelet activities of Ramatroban.Investigational
RamiprilRamipril may increase the hypotensive activities of Treprostinil.Approved
RasagilineRasagiline may increase the hypotensive activities of Treprostinil.Approved
RemikirenRemikiren may increase the hypotensive activities of Treprostinil.Approved
RescinnamineTreprostinil may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Treprostinil.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Treprostinil is combined with Resveratrol.Experimental, Investigational
ReteplaseThe risk or severity of adverse effects can be increased when Reteplase is combined with Treprostinil.Approved
ReviparinTreprostinil may increase the anticoagulant activities of Reviparin.Approved
RidogrelTreprostinil may increase the antiplatelet activities of Ridogrel.Approved
RifampicinThe serum concentration of Treprostinil can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Treprostinil can be decreased when it is combined with Rifapentine.Approved
RilmenidineTreprostinil may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatTreprostinil may increase the hypotensive activities of Riociguat.Approved
RitonavirThe serum concentration of Treprostinil can be increased when it is combined with Ritonavir.Approved, Investigational
RituximabTreprostinil may increase the hypotensive activities of Rituximab.Approved
RivaroxabanTreprostinil may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Treprostinil is combined with Rofecoxib.Investigational, Withdrawn
RosiglitazoneThe risk or severity of adverse effects can be increased when Rosiglitazone is combined with Treprostinil.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Treprostinil.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Treprostinil is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Treprostinil is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Treprostinil is combined with Salsalate.Approved
SaprisartanTreprostinil may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirTreprostinil may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SCH-530348Treprostinil may increase the antiplatelet activities of SCH-530348.Investigational
SecobarbitalThe serum concentration of Treprostinil can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Treprostinil.Approved, Investigational, Vet Approved
SelexipagTreprostinil may increase the hypotensive activities of Selexipag.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Treprostinil is combined with Seratrodast.Approved, Investigational
SevofluraneTreprostinil may increase the antiplatelet activities of Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Treprostinil.Approved, Investigational
SitaxentanTreprostinil may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SorafenibThe metabolism of Treprostinil can be decreased when combined with Sorafenib.Approved, Investigational
SotalolTreprostinil may increase the QTc-prolonging activities of Sotalol.Approved
SpiraprilTreprostinil may increase the hypotensive activities of Spirapril.Approved
SRT501The risk or severity of adverse effects can be increased when Treprostinil is combined with SRT501.Investigational
StiripentolThe serum concentration of Treprostinil can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Treprostinil.Approved
SulfadiazineThe metabolism of Treprostinil can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Treprostinil can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Treprostinil can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Treprostinil is combined with Sulindac.Approved
SulodexideTreprostinil may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Suprofen.Approved, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Treprostinil.Approved, Investigational
TelavancinTreprostinil may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinTreprostinil may increase the QTc-prolonging activities of Telithromycin.Approved
TelmisartanTreprostinil may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilTreprostinil may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenecteplaseThe risk or severity of adverse effects can be increased when Tenecteplase is combined with Treprostinil.Approved
TenoxicamThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Treprostinil is combined with Teriflunomide.Approved
TerlipressinTreprostinil may increase the hypotensive activities of Terlipressin.Approved, Investigational
TesmilifeneTreprostinil may increase the antiplatelet activities of Tesmilifene.Investigational
TetrabenazineTreprostinil may increase the QTc-prolonging activities of Tetrabenazine.Approved
ThioridazineTreprostinil may increase the QTc-prolonging activities of Thioridazine.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tiaprofenic acid.Approved
TiboloneTreprostinil may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe metabolism of Treprostinil can be decreased when combined with Ticagrelor.Approved
TiclopidineTreprostinil may increase the antiplatelet activities of Ticlopidine.Approved
TicrynafenTreprostinil may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Treprostinil.Approved
TinoridineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tinoridine.Investigational
TinzaparinThe risk or severity of adverse effects can be increased when Tinzaparin is combined with Treprostinil.Approved
TirofibanTreprostinil may increase the antiplatelet activities of Tirofiban.Approved
TolazolineTreprostinil may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Treprostinil can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Treprostinil.Approved
TorasemideTorasemide may increase the hypotensive activities of Treprostinil.Approved
ToremifeneTreprostinil may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrandolaprilTreprostinil may increase the hypotensive activities of Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Treprostinil.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Treprostinil.Approved
TrapidilTreprostinil may increase the antiplatelet activities of Trapidil.Approved
TravoprostTravoprost may increase the hypotensive activities of Treprostinil.Approved
TrichlormethiazideTreprostinil may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TriflusalTreprostinil may increase the antiplatelet activities of Triflusal.Approved
TrimazosinTreprostinil may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanTreprostinil may increase the hypotensive activities of Trimethaphan.Approved
TrimethoprimThe metabolism of Treprostinil can be decreased when combined with Trimethoprim.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Trisalicylate-choline.Approved
UdenafilUdenafil may increase the antihypertensive activities of Treprostinil.Approved, Investigational
UnoprostoneTreprostinil may increase the hypotensive activities of Unoprostone.Approved
UrokinaseThe risk or severity of adverse effects can be increased when Urokinase is combined with Treprostinil.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Treprostinil is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe metabolism of Treprostinil can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Treprostinil can be decreased when combined with Valsartan.Approved, Investigational
VandetanibTreprostinil may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the antihypertensive activities of Treprostinil.Approved
VemurafenibTreprostinil may increase the QTc-prolonging activities of Vemurafenib.Approved
VinpocetineTreprostinil may increase the hypotensive activities of Vinpocetine.Investigational
VorapaxarTreprostinil may increase the antiplatelet activities of Vorapaxar.Approved
VoriconazoleThe metabolism of Treprostinil can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinTreprostinil may increase the anticoagulant activities of Warfarin.Approved
XimelagatranTreprostinil may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
XylometazolineTreprostinil may increase the hypotensive activities of Xylometazoline.Approved
Ym150Treprostinil may increase the anticoagulant activities of Ym150.Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Treprostinil.Approved, Vet Approved
ZafirlukastThe metabolism of Treprostinil can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Treprostinil is combined with Zileuton.Approved, Investigational, Withdrawn
ZiprasidoneTreprostinil may increase the QTc-prolonging activities of Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Treprostinil is combined with Zomepirac.Withdrawn
ZuclopenthixolTreprostinil may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Hitesh Batra, Raju Penmasta, Vijay Sharma, Sudersan M. Tuladhar, David A. Walsh, “TREPROSTINIL PRODUCTION.” U.S. Patent US20110319641, issued December 29, 2011.

US20110319641
General ReferencesNot Available
External Links
ATC CodesB01AC21
AHFS Codes
  • 24:12.92
PDB EntriesNot Available
FDA labelDownload (223 KB)
MSDSDownload (17.4 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.994
Blood Brain Barrier+0.5541
Caco-2 permeable+0.5838
P-glycoprotein substrateSubstrate0.7733
P-glycoprotein inhibitor INon-inhibitor0.719
P-glycoprotein inhibitor IINon-inhibitor0.7518
Renal organic cation transporterNon-inhibitor0.8064
CYP450 2C9 substrateNon-substrate0.7811
CYP450 2D6 substrateNon-substrate0.8144
CYP450 3A4 substrateSubstrate0.6538
CYP450 1A2 substrateInhibitor0.7312
CYP450 2C9 inhibitorNon-inhibitor0.8496
CYP450 2D6 inhibitorNon-inhibitor0.9127
CYP450 2C19 inhibitorNon-inhibitor0.6214
CYP450 3A4 inhibitorNon-inhibitor0.6587
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6885
Ames testNon AMES toxic0.8716
CarcinogenicityNon-carcinogens0.9452
BiodegradationNot ready biodegradable0.7495
Rat acute toxicity2.0749 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9588
hERG inhibition (predictor II)Inhibitor0.7664
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • United therapeutics corp
Packagers
Dosage forms
FormRouteStrength
Tablet, extended releaseOral.125 mg/1
Tablet, extended releaseOral.25 mg/1
Tablet, extended releaseOral1 mg/1
Tablet, extended releaseOral2.5 mg/1
Tablet, extended releaseOral5 mg/1
Injection, solutionIntravenous; Subcutaneous100 mg/20mL
Injection, solutionIntravenous; Subcutaneous20 mg/20mL
Injection, solutionIntravenous; Subcutaneous200 mg/20mL
Injection, solutionIntravenous; Subcutaneous50 mg/20mL
SolutionIntravenous; Subcutaneous1 mg
SolutionIntravenous; Subcutaneous10 mg
SolutionIntravenous; Subcutaneous2.5 mg
SolutionIntravenous; Subcutaneous5 mg
InhalantOral1.74 mg/2.9mL
Prices
Unit descriptionCostUnit
Remodulin 10 mg/ml vial737.0USD ml
Remodulin 5 mg/ml vial368.5USD ml
Tyvaso inhalation starter kit185.8USD ml
Remodulin 2.5 mg/ml vial184.25USD ml
Tyvaso 1.74 mg/2.9 ml solution174.55USD ml
Tyvaso inhalation refill kit165.68USD ml
Remodulin 1 mg/ml vial73.7USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5153222 No1994-10-062014-10-06Us
US6521212 No1998-11-132018-11-13Us
US6756033 No1998-11-132018-11-13Us
US6765117 No1997-10-242017-10-24Us
US7417070 No2006-07-302026-07-30Us
US7544713 No2004-07-142024-07-14Us
US7999007 No2009-03-292029-03-29Us
US8252839 No2004-05-242024-05-24Us
US8349892 No2011-01-222031-01-22Us
US8410169 No2010-02-132030-02-13Us
US8497393 No2008-12-152028-12-15Us
US8653137 No2008-09-052028-09-05Us
US8658694 No2008-09-052028-09-05Us
US8747897 No2009-10-082029-10-08Us
US9050311 No2004-05-242024-05-24Us
US9199908 No2004-05-242024-05-24Us
US9278901 No2004-05-242024-05-24Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityInsoluble at 25°CNot Available
logP4.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00731 mg/mLALOGPS
logP3.53ALOGPS
logP4ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)3.76ChemAxon
pKa (Strongest Basic)-1.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area86.99 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity108 m3·mol-1ChemAxon
Polarizability45.74 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenoxyacetic acid derivatives. These are compounds containing an anisole where the methane group is linked to an acetic acid or a derivative.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenoxyacetic acid derivatives
Direct ParentPhenoxyacetic acid derivatives
Alternative Parents
Substituents
  • Phenoxyacetate
  • Tetralin
  • Fatty alcohol
  • Alkyl aryl ether
  • Fatty acyl
  • Cyclic alcohol
  • Secondary alcohol
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
Receptor for prostacyclin (prostaglandin I2 or PGI2). The activity of this receptor is mediated by G(s) proteins which activate adenylate cyclase.
Gene Name:
PTGIR
Uniprot ID:
P43119
Molecular Weight:
40955.485 Da
References
  1. Falcetti E, Hall SM, Phillips PG, Patel J, Morrell NW, Haworth SG, Clapp LH: Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010 Nov 1;182(9):1161-70. doi: 10.1164/rccm.201001-0011OC. Epub 2010 Jul 9. [PubMed:20622039 ]
  2. Sprague RS, Bowles EA, Hanson MS, DuFaux EA, Sridharan M, Adderley S, Ellsworth ML, Stephenson AH: Prostacyclin analogs stimulate receptor-mediated cAMP synthesis and ATP release from rabbit and human erythrocytes. Microcirculation. 2008 Jul;15(5):461-71. doi: 10.1080/10739680701833804. [PubMed:18574748 ]
  3. Olschewski H, Rose F, Schermuly R, Ghofrani HA, Enke B, Olschewski A, Seeger W: Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther. 2004 May;102(2):139-53. [PubMed:15163595 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Ligand-activated transcription factor. Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Has a preference for poly-unsaturated fatty acids, such as gamma-linoleic acid and eicosapentanoic acid. Once activated by a ligand, the receptor binds to promoter elements of target genes. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as ...
Gene Name:
PPARD
Uniprot ID:
Q03181
Molecular Weight:
49902.99 Da
References
  1. Ali FY, Egan K, FitzGerald GA, Desvergne B, Wahli W, Bishop-Bailey D, Warner TD, Mitchell JA: Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts. Am J Respir Cell Mol Biol. 2006 Feb;34(2):242-6. Epub 2005 Oct 20. [PubMed:16239641 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
Receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation.
Gene Name:
P2RY12
Uniprot ID:
Q9H244
Molecular Weight:
39438.355 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Gotzkowsky SK, Dingemanse J, Lai A, Mottola D, Laliberte K: Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers. J Clin Pharmacol. 2010 Jul;50(7):829-34. doi: 10.1177/0091270009351173. Epub 2010 Feb 4. [PubMed:20133511 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 03, 2016 02:54